Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

NCT01828008 is registered in ClinicalTrials.gov with Han weidong as lead sponsor.

NCT NCT01828008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01828008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Lead sponsor
Han weidong
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2013
Completion date
May 31, 2015
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas